Clinical Trials Logo

Dexterity clinical trials

View clinical trials related to Dexterity.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06167382 Completed - Healthy Adults Clinical Trials

The Effect of Arm Ergometer Exercise on Dexterity

Start date: December 25, 2022
Phase: N/A
Study type: Interventional

The goal of this single group assessment study is to investigate acute effect of arm ergometer exercise intensity on dexterity and hand reaction time in healthy male or female participants aged 18-35. - Knowing the acute effect and change of hand dexterity and reaction times of individuals with arm ergometer intensities applied at different intensities provides us with data that can be processed and used in neurological, orthopedic patient groups and geriatric cases during the rehabilitation process. - The positive gains enable us to obtain effective and observable results in the rehabilitation progression of individuals and in parameters such as muscle strength and endurance, quality of life, depression, chronic pain. Participants who accepted the voluntary basis will be taken and the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) will be filled. After all evaluations were made to the participants, 3 different exercise intensities; maximum heart rates; 60%, 70%, 80% will do arm ergometer exercises. - ROM measurements - Muscle strength tests - Grip strength measurement (Jamar hand dynamometer) - Dexterity and Function tests (Nelson Hand Reaction Test - Purdue Pegboard Test - Minnesota Manual Dexterity Test) evaluation parameters will be applied before, immediately after and 15 minutes after each exercise intervention.

NCT ID: NCT05880745 Completed - Multiple Sclerosis Clinical Trials

The Effect of the Level of Hand Fatigability on Multiple Sclerosis on General Fatigue and Functionality

Start date: December 8, 2018
Phase: N/A
Study type: Interventional

The objective of this study is to investigate the effect of the level of hand fatigability on general fatigue and functionality by comparing Relapsing-Remitting Multiple Sclerosis individuals with age and sex-matched healthy individuals. 23 RRMS and 23 healthy people (mean age 40.08, 21 females, mean time since diagnosis 9.43 years, mean Expanded Disability Status Scale 3.23) were included in the study. To examine participants' fatigability level; for gross and pinch-grip Dynamic and Static Fatigue Index, for manual dexterity and functionality level Scale for the Assessment and Rating of Ataxia (SARA), Nine Hole Peg Test (NHPT) and Dexterity Questionnaire-24 (DextQ-24) were used. While Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS) were used to examine general fatigue, Beck Depression Inventory (BDI) was used to assess emotional status. The mean age of healthy individuals with RRMS was 40.08 ± 9.81 years, and the EDSS means of individuals with RRMS was 3.23 ± 1.47. 21 of both groups were female and 2 were male. It was determined that the difference between MS individuals and healthy individuals' SARA, NHPT, FSS and FIS averages, initial and final strength values was statistically significant (p≤0.05), and the decrease in force in individuals with RRMS was higher than in healthy individuals. However, there was no difference between RRMS and healthy individuals in terms of fatigability levels examined with the Dynamic and Static Fatigue Index (p>0.05). While the relationship of Static and Dynamic Fatigue Index with FSS and FIS was not statistically significant, the relationship was significant with DextQ-24's dressing, daily activities and TV/CD/DVD subsections (p<0.05). In individuals with early RRMS, there is a decrease in the repetitive (dynamic) and continuous (static) contractions of the rough and pinch grip strength, and this decrease is related to the negative impact on the daily living activities and functionality of the individuals. In particular, motor fatigue should be addressed from the early stages of rehabilitation programs that will be planned to maintain the active participation of individuals with RRMS in their daily living activities. To show motor fatigue with indices, further studies with different fatigue indices and individuals with RRMS at different EDSS levels are needed.

NCT ID: NCT03763955 Completed - Parkinson Disease Clinical Trials

Effectiveness of MIRT on Hand and Finger Dexterity in PD Patients

H_F_ D_PD_MIRT
Start date: January 1, 2015
Phase:
Study type: Observational

Aims of the study are (1) to evaluate the effectiveness of a specific OT treatment aimed to enhance finger and hand dexterity and (2) its impact on daily living autonomy of PD patients.

NCT ID: NCT03525561 Completed - Hypoxia Clinical Trials

Acetazolamide and Exercise Performance at Altitude

Start date: October 10, 2018
Phase: Early Phase 1
Study type: Interventional

The goals of the present study are to evaluate whether the most common, and effective, treatment for acute mountain sickness (AMS), acetazolamide (AZ), has a negative, positive, or no influence on exercise performance, cognitive performance, or manual dexterity in young healthy subjects during simulated altitude exposure. AMS represents a serious challenge to the health and performance of the Warfighter who may need to rapidly deploy to high altitude. However, there have been concerns that AZ might alter or impair endurance exercise performance, and possibly fine motor skills. These would represent major limitations to the use of this drug in a Warfighter who has a specific timeframe in which to accomplish mission tasks. In the present project, we will use exposure to simulated altitude in the USARIEM hypobaric chamber to quantify the impact, if any, of AZ on endurance exercise performance following rapid ascent to 3500 meters (m) in unacclimatized lowlander volunteers. The study will be conducted using a randomized, single-blind, placebo-controlled crossover study design. Ten male and female volunteers will complete one orientation day, one VO2peak day, three days of familiarization testing at sea level (SL), then two rounds of experimental testing. Each round of experimental testing consists of six days including four days to establish baseline euhydration, followed by a 30 hour (hr) exposure to 3500 m. Volunteers will have a two week break between experimental testing rounds for washout of any effects of altitude acclimation. During one experimental round, volunteers will take two doses of AZ each day (Phase 1: 250 mg/dose,500 mg/day, Phase 2: 125 mg/dose, 250 mg/day) starting 48 hr prior to their altitude exposure and continuing for the 30 hr stay at high altitude. During the other experimental condition, volunteers will be given a placebo at the same time points as the doses of AZ. Prior to altitude exposure, AMS will be evaluated and volunteers will then ascend to a simulated altitude of 3500 m, where they will remain for 30 hr. Volunteers will rest at altitude for an hr, after which they will complete an AMS questionnaire, resting ventilation measurements, provide a blood sample and complete cognitive and finger dexterity testing. Subjects will then perform 15 minutes (min) of steady state (SS) treadmill exercise at 40-45% of SL VO2peak and a 2 mile treadmill time trial (TT). Volunteers will stay overnight in the hypobaric chamber with research staff supervision. The following morning, metabolic and blood measurements will again be completed, after which volunteers will perform the exercise testing for a second time. Cognitive and finger dexterity testing will be performed before volunteers return to sea level (i.e., "descend" from the simulated altitude). The results of the proposed study will, for the first time, provide quantitative evidence regarding whether AZ treatment impairs endurance exercise performance in the context of a Warfighter-relevant endurance exercise task.